About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Gabapentin Treatment of Cannabis Dependence | Clinical Trials | Clareo Health

Back to clinical trial search

COMPLETEDPhase 2NCT00395044

Gabapentin Treatment of Cannabis Dependence

This is a study to evaluate the efficacy of the medication gabapentin in treating persons with cannabis dependence.

Lead sponsor: The Scripps Research Institute•1 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

The Scripps Research Institute

Collaborators

National Institute on Drug Abuse (NIDA)

This is a 12-week, double blind, placebo controlled, dose ranging study to evaluate the efficacy of gabapentin in treating outpatients with cannabis dependence. Counseling and research assessments occur weekly throughout the 12-week treatment phase.

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Males or females age 18-65 with cannabis dependence
•Meets DSM-IV-TR criteria for Cannabis Dependence
•Smoked marijuana at least once a week in the 90 days prior to study participation
•Willing to attend 12 weekly study visits and 1 follow-up visit

Exclusion Criteria

•Currently meets DSM-IV-TR criteria for dependence on illicit substances other than cannabis
•Significant medical disorders that will increase potential risk or interfere with study participation
•Women with childbearing potential who are pregnant, nursing, or refuse to use a reliable method of birth control
•Treatment with an investigational drug in the last month

Related studies

Cannabis Abstinence and Neurocognitive Assessment in Adolescence

NCT07160153 · Cannabis Dependence, Harmful Use, and more

Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning

NCT01730781 · Schizophrenia, Cannabis Dependence, and more

Active Not RecruitingNA

Breathwork-assisted Treatment for Cannabis Use Disorder

NCT05219825 · Addiction, Substance Abuse, and more

COMPLETEDPhase 4

Reducing Cannabis Overuse With Prazosin

NCT04721353 · Cannabis Dependence, Posttraumatic Stress Disorder, and more

COMPLETEDEARLY Phase 1

Brain Imaging of Cannabinoid Receptors

NCT03204305 · Cannabis Use Disorder, Cannabis Dependence, Continuous

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: February 10, 2017Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE2

Enrollment50

Start dateAug 2006

Last updatedFeb 10, 2017

Condition

Cannabis Dependence

Locations shown

The Scripps Research Institute

La Jolla, California

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 10, 2017Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions